ClinicalTrials.gg
CompletedNCT05110261CHIMESUpdated Oct 15, 2026

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China

A Phase 3 interventional study of Nirsevimab and Placebo in Lower Respiratory Tract Infection, sponsored by AstraZeneca. Completed at 30 sites in China. Open to participants aged 0 Years to 1 Year, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
0 Years to 1 Year
Sex
All
01

Study summary

The purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China

Read the detailed description

This is a Phase 3 randomized, double-blind, placebo-controlled, single-dose study to determine if nirsevimab will prevent medically attended RSV-confirmed LRTI in healthy preterm and term infants entering their first RSV season. The population to be enrolled is healthy preterm and term infants > 29 weeks 0 days GA entering their first RSV season, who would not receive RSV prophylaxis based on the American Academy of Pediatrics (AAP) or other local or national guidelines. Approximately 800 subjects will be randomized 2:1 to receive a single IM dose of nirsevimab 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg) (N = 530) or placebo (N = 270). Randomization will be stratified by subject age at the time of randomization (≤ 3 months, > 3 to ≤ 6 months, > 6 months), and by GA (\< 35 weeks GA, ≥ 35 weeks GA). Enrollment of infants > 6 months of age will be limited to approximately 100. All subjects will be followed through 1 year after dose administration. An independent data monitoring committee will review safety data regularly and make recommendations regarding further study conduct. Around 40 investigational study centres participate in the study.

02

Conditions studied

  • Lower Respiratory Tract Infection

Keywords

  • Respiratory Syncytial Viral (RSV)
  • Efficacy
  • Safety
  • Nirsevimab
  • healthy Chinese preterm and term infants
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 1 Year
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Chinese preterm and term infants in their first year of life and born ≥ 29 weeks 0 days GA (infants who have an underlying illness such as cystic fibrosis or Down syndrome with no other risk factors are eligible)
  2. Infants who are entering their first RSV season at the time of screening
  3. Written and any locally required authorization obtained from the subject's parent(s)/legal representative(s) prior to performing any protocol-related procedures, including screening evaluations
  4. Subject's parent(s)/legal representative(s) able to understand and comply with the requirements of the protocol including follow-up visits as judged by the Investigator
  5. Subject is available to complete the follow up period, which will be approximately 1 year after receipt of product

Exclusion criteria

Exclusion Criteria:

  1. Any fever (≥ 100.4°F [≥ 38.0°C], regardless of route) or acute illness within 7 days prior to product administration
  2. Any history of LRTI or active LRTI prior to, or at the time of, randomization
  3. Known history of RSV infection or active RSV infection prior to, or at the time of, randomization
  4. Any drug therapy (chronic or other) within 7 days prior to randomization or expected receipt during the study with the exception of: a) multivitamins and iron; b) infrequent use of over-the-counter (OTC) medications for the systemic treatment of common childhood symptoms (eg, pain relievers) that may be permitted according to the judgment of the Investigator
  5. Any current or expected receipt of agents including (except for the use of topical steroids according to the judgment of the Investigator)
  6. History of receipt of blood products, or immunoglobulin products, or expected receipt through the duration of the study
  7. Hospitalization at the time of randomization, unless discharge is expected within the 7 days after randomization
  8. Known renal impairment
  9. Known hepatic dysfunction including known or suspected active or chronic hepatitis infection
  10. History of CLD/bronchopulmonary dysplasia
  11. congenital anomaly of the respiratory tract
  12. CHD, except for children with uncomplicated CHD (eg, patent ductus arteriosus, small septal defect)
  13. Chronic seizure, or evolving or unstable neurologic disorder
  14. Prior history of a suspected or actual acute life-threatening event
  15. Known immunodeficiency, including (HIV)
  16. Mother with HIV infection (unless the child has been proven to be not infected)
  17. Any known allergy or history of allergic reaction to immunoglobulin products, blood products, or other foreign proteins, or history of allergic reaction
  18. Receipt of palivizumab or other RSV mAb or any RSV vaccine, including maternal RSV vaccination
  19. Receipt of any monoclonal or polyclonal antibody (for example, immune globulin, IV immunoglobulin) or anticipated use during the study
  20. Receipt of any investigational product
  21. Concurrent enrollment in another interventional study
  22. Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of study results
  23. Children of employees of the Sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
800 participants (actual)

Study arms

  • Experimental
    Nirsevimab

    Subjects will be randomized 2:1 to receive a single IM dose of nirsevimab or placebo.

    Drug: Nirsevimab

  • Placebo comparator
    Placebo

    Subjects will be randomized 2:1 to receive a single IM dose of nirsevimab or placebo.

    Drug: Placebo

Interventions

  • Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.

    Also known as: MEDI8897

  • DrugPlacebo

    Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)

06

What researchers measure

Primary outcomes

  1. Incidence of medically attended LRTI due to RT-PCR-confirmed RSV

    Incidence of all medically attended LRTI (inpatient and outpatient) due to RT-PCR-confirmed RSV through 150 days after dosing (ie, during a typical 5-month RSV season)

    Time frame: Day 1 to Day 151

Secondary outcomes

  1. Incidence of LRTI hospitalization due to RT-PCR confirmed RSV

    To assess the efficacy of nirsevimab in reducing hospitalizations due to protocol-defined LRTI caused by RT-PCR-confirmed RSV, compared to placebo

    Time frame: Day 1 to Day 151

  2. Incidence of medically attended LRTI (protocol defined) due to RT-PCR-confirmed RSV

    To assess the efficacy of nirsevimab in reducing protocol-defined LRTI caused by RT-PCR-confirmed RSV, compared to placebo

    Time frame: Day 1 to Day 151

  3. Safety and tolerability

    Safety and tolerability of nirsevimab as assessed by the occurrence of all treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAE) Other safety assessments will include the occurrence of Adverse Event of Special Interest (AESIs) and New Onset Chronic Diseases (NOCDs).

    Time frame: Day 1 to Day 361

  4. Summary of nirsevimab serum concentrations

    To evaluate serum concentrations of nirsevimab.

    Time frame: Day 1, Day 15, Day 151 & Day 361

  5. Incidence of ADA to nirsevimab in serum

    To evaluate ADA responses to nirsevimab in serum.

    Time frame: Day 1, Day 151 & Day 361

07

Study locations

30 sites
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changde, 415000, China
  • Research Site
    Changsha, 410005, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, 510150, China
  • Research Site
    Guangzhou, 510280, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hangzhou, 310013, China
  • Research Site
    Jiaxing, 314000, China
  • Research Site
    Kunming, 650101, China
  • Research Site
    Langfang, 065000, China
  • Research Site
    Linfen, 041099, China
  • Research Site
    Linfen, 41081, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Ningbo, 315012, China
  • Research Site
    Sanmenxia, 472000, China
  • Research Site
    Sanya, 572000, China
  • Research Site
    Shantou, 515041, China
  • Research Site
    Shaoxing, 311800, China
  • Research Site
    Shenzhen, 518106, China
  • Research Site
    Suzhou, 215002, China
  • Research Site
    Tangshan, 63003, China
  • Research Site
    Tianjin, 300201, China
  • Research Site
    Wenzhou, 325027, China
  • Research Site
    Xinxiang, 453000, China
  • Research Site
    Zhengzhou, 450018, China
  • Research Site
    Zhongshan, 528400, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Nov 2025, 48 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2021
First posted
Nov 5, 2021
StartActual
Nov 24, 2021
Primary completionActual
Nov 24, 2025
CompletionActual
Nov 24, 2025
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and references
1 update, last Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Minor edits only
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05110261
Lead sponsor
AstraZeneca
Collaborators
IQVIA RDS Inc.
Responsible party
Sponsor
First posted
Nov 5, 2021
Start date
Nov 24, 2021
Primary completion
Nov 24, 2025
Completion
Nov 24, 2025
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion